Ltx-109 is a novel agent for nasal decolonization of methicillin-resistant and -sensitive staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 145-151

  Nilsson, Anna C ^a   Janson, Håkan ^a,c   Wold, Hedda ^b   Fugelli, Anders ^b   Andersson, Karin ^a   Håkangård, Camilla ^a   Olsson, Pernilla ^a   Olsen, Wenche Marie ^b  

^a LUND UNIVERSITY   (Sweden)

^b LYTIX BIOPHARMA AS   (Norway)

^c CENTRAL HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; ANTIINFECTIVE AGENT; LTX 109; UNCLASSIFIED DRUG; OLIGOPEPTIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL LOAD; COLONY FORMING UNIT; COMMON COLD; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; NONHUMAN; NOSE CAVITY; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE HEMORRHAGE; PRURITUS; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; INTRANASAL DRUG ADMINISTRATION; MICROBIOLOGY; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; YOUNG ADULT;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; NASAL CAVITY; OLIGOPEPTIDES; STAPHYLOCOCCAL INFECTIONS; YOUNG ADULT;

EID: 84920130753     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03513-14     Document Type: Article

References (47)

1. Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, Nouwen JL. 2005. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 5:751-762. http://dx.doi.org/10 .1016/S1473-3099(05)70295-4.
2. Williams RE, Jevons MP, Shooter RA, Hunter CJ, Girling JA, Griffiths JD, Taylor GW. 1959. Nasal staphylococci and sepsis in hospital patients. Br Med J 2:658-662. http://dx.doi.org/10.1136/bmj.2.5153.658.
3. Kluytmans JA, Mouton JW, Ijzerman EP, Vandenbroucke-Grauls CM, Maat AW, Wagenvoort JH, Verbrugh HA. 1995. Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. J Infect Dis 171:216-219. http://dx.doi.org/10.1093/infdis/171.1 .216.
4. Perl TM, Cullen JJ, Wenzel RP, Zimmerman MB, Pfaller MA, Sheppard D, Twombley J, French PP, Herwaldt LA. 2002. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections.NEngl J Med 346: 1871-1877. http://dx.doi.org/10.1056/NEJMoa003069.
5. Munoz P, Hortal J, Giannella M, Barrio JM, Rodriguez-Creixems M, Perez MJ, Rincon C, Bouza E. 2008. Nasal carriage of S. aureus increases the risk of surgical site infection after major heart surgery. J Hosp Infect 68:25-31. http://dx.doi.org/10.1016/j.jhin.2007.08.010.
6. Bode LG, Kluytmans JA, Wertheim HF, Bogaers D, Vandenbroucke-Grauls CM, Roosendaal R, Troelstra A, Box AT, Voss A, van der Tweel I, van Belkum A, Verbrugh HA, Vos MC. 2010. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med 362:9-17. http://dx.doi.org/10.1056/NEJMoa0808939.
7. Kluytmans JA, Wertheim HF. 2005. Nasal carriage of Staphylococcus aureus and prevention of nosocomial infections. Infection 33:3-8. http: //dx.doi.org/10.1007/s15010-005-4012-9.
8. Coates T, Bax R, Coates A. 2009. Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses and future prospects. J Antimicrob Chemother 64:9-15. http://dx.doi.org/10.1093/jac/dkp159.
9. del Rio A, Cervera C, Moreno A, Moreillon P, Miro JM. 2009. Patients at risk of complications of Staphylococcus aureus bloodstream infection. Clin Infect Dis 48(Suppl 4):S246-S253. http://dx.doi.org/10 .1086/598187.
10. Tai YJ, Borchard KL, Gunson TH, Smith HR, Vinciullo C. 2013. Nasal carriage of Staphylococcus aureus in patients undergoing Mohs micrographic surgery is an important risk factor for postoperative surgical site infection: a prospective randomised study. Australas J Dermatol 54:109-114. http://dx.doi.org/10.1111/ajd.12028.
11. Sandri AM, Dalarosa MG, Ruschel de Alcantara L, da Silva Elias L, Zavascki AP. 2006. Reduction in incidence of nosocomial methicillinresistant Staphylococcus aureus (MRSA) infection in an intensive care unit: role of treatment with mupirocin ointment and chlorhexidine baths for nasal carriers of MRSA. Infect Control Hosp Epidemiol 27:185-187. http: //dx.doi.org/10.1086/500625.
12. van Rijen M, Bonten M, Wenzel R, Kluytmans J. 2008. Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database Syst Rev CD006216. http://dx.doi.org/10.1002 /14651858.CD006216.pub2.
13. Bocher S, Skov RL, Knudsen MA, Guardabassi L, Molbak K, Schouenborg P, Sorum M, Westh H. 2010. The search and destroy strategy prevents spread and long-term carriage of methicillin-resistant Staphylococcus aureus: results from the follow-up screening of a large ST22 (EMRSA 15) outbreak in Denmark. Clin Microbiol Infect 16:1427-1434. http://dx.doi.org/10.1111/j.1469-0691.2010.03137.x.
14. Babu T, Rekasius V, Parada JP, Schreckenberger P, Challapalli M. 2009. Mupirocin resistance among methicillin-resistant Staphylococcus aureuscolonized patients at admission to a tertiary care medical center. J Clin Microbiol 47:2279-2280. http://dx.doi.org/10.1128/JCM.01834-08.
15. Haug BE, Strom MB, Svendsen JS. 2007. The medicinal chemistry of short lactoferricin-based antibacterial peptides. Curr Med Chem 14:1-18. http://dx.doi.org/10.2174/092986707779313435.
16. Svenson J, Stensen W, Brandsdal BO, Haug BE, Monrad J, Svendsen JS. 2008. Antimicrobial peptides with stability toward tryptic degradation. Biochemistry 47:3777-3788. http://dx.doi.org/10.1021/bi7019904.
17. Haug BE, Stensen W, Kalaaji M, Rekdal O, Svendsen JS. 2008. Synthetic antimicrobial peptidomimetics with therapeutic potential. J Med Chem 51:4306-4314. http://dx.doi.org/10.1021/jm701600a.
18. Isaksson J, Brandsdal BO, Engqvist M, Flaten GE, Svendsen JS, Stensen W. 2011. A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption. J Med Chem 54:5786-5795. http://dx.doi.org/10.1021/jm200450h.
19. st Intersci Conf Antimicob Agents Chemother, Boston, MA.
20. Ryge TS, Frimodt-Moller N, Hansen PR. 2008. Antimicrobial activities of twenty lysine-peptoid hybrids against clinically relevant bacteria and fungi. Chemotherapy 54:152-156. http://dx.doi.org/10.1159/000119707.
21. th Intersci Conf Antimicrob Agents Chemother, San Francisco, CA.
22. Saravolatz LD, Pawlak J, Johnson L, Bonilla H, Saravolatz LD, II, Fakih MG, Fugelli A, Olsen WM. 2012. In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycinintermediate, vancomycin-resistant, daptomycin-nonsusceptible, and li-nezolid-nonsusceptible Staphylococcus aureus . Antimicrob Agents Chemother 56:4478-4482. http://dx.doi.org/10.1128/AAC.00194-12.
23. nd Intersci Conf Antimicrob Agents Chemother, Denver, CO.
24. th Eur Congr Clin Microbiol Infect Dis, Helsinki, Finland.
25. Larsson AK, Gustafsson E, Nilsson AC, Odenholt I, Ringberg H, Melander E. 2011. Duration of methicillin-resistant Staphylococcus aureus colonization after diagnosis: a four-year experience from southern Sweden. Scand J Infect Dis 43:456-462. http://dx.doi.org/10.3109/00365548 .2011.562530.
26. Reischl U, Linde HJ, Metz M, Leppmeier B, Lehn N. 2000. Rapid identification of methicillin-resistant Staphylococcus aureus and simultaneous species confirmation using real-time fluorescence PCR. J Clin Microbiol 38:2429-2433.
27. Shopsin B, Gomez M, Montgomery SO, Smith DH, Waddington M, Dodge DE, Bost DA, Riehman M, Naidich S, Kreiswirth BN. 1999. Evaluation of protein A gene polymorphic region DNA sequencing for typing of Staphylococcus aureus strains. J Clin Microbiol 37:3556-3563.
28. Harmsen D, Claus H, Witte W, Rothganger J, Claus H, Turnwald D, Vogel U. 2003. Typing of methicillin-resistant Staphylococcus aureus in a university hospital setting by using novel software for spa repeat determination and database management. J Clin Microbiol 41:5442-5448. http: //dx.doi.org/10.1128/JCM.41.12.5442-5448.2003.
29. Richards MJ, Edwards JR, Culver DH, Gaynes RP. 2000. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol 21:510-515. http://dx.doi.org/10 .1086/501795.
30. Lowy FD. 1998. Staphylococcus aureus infections. N Engl J Med 339:520-532. http://dx.doi.org/10.1056/NEJM199808203390806.
31. Mintjes-de Groot AJ, van Hassel CA, Kaan JA, Verkooyen RP, Verbrugh HA. 2000. Impact of hospital-wide surveillance on hospitalacquired infections in an acute-care hospital in the Netherlands. J Hosp Infect 46:36-42. http://dx.doi.org/10.1053/jhin.2000.0755.
32. VandenBergh MF, Kluytmans JA, van Hout BA, Maat AP, Seerden RJ, McDonnel J, Verbrugh HA. 1996. Cost-effectiveness of perioperative mupirocin nasal ointment in cardiothoracic surgery. Infect Control Hosp Epidemiol 17:786-792. http://dx.doi.org/10.1086/647237.
33. Pittet D, Wenzel RP. 1995. Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths. Arch Intern Med 155:1177-1184.
34. Kluytmans JA, Mouton JW, VandenBergh MF, Manders MJ, Maat AP, Wagenvoort JH, Michel MF, Verbrugh HA. 1996. Reduction of surgicalsite infections in cardiothoracic surgery by elimination of nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol 17:780-785.
35. von Eiff C, Becker K, Machka K, Stammer H, Peters G. 2001. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study group.NEngl J Med 344:11-16. http://dx.doi.org/10.1056/NEJM200101043440102.
36. Corbella X, Dominguez MA, Pujol M, Ayats J, Sendra M, Pallares R, Ariza J, Gudiol F. 1997. Staphylococcus aureus nasal carriage as a marker for subsequent staphylococcal infections in intensive care unit patients. Eur J Clin Microbiol Infect Dis 16:351-357. http://dx.doi.org/10.1007 /BF01726362.
37. Doebbeling BN, Breneman DL, Neu HC, Aly R, Yangco BG, Holley HP, Jr, Marsh RJ, Pfaller MA, McGowan JE, Jr, Scully BE, Reagan DR, Wenzel RP, the Mupirocin Collaborative Study Group. 1993. Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. The Mupirocin Collaborative Study Group. Clin Infect Dis 17:466-474. http://dx.doi.org /10.1093/clinids/17.3.466.
38. Huang SS, Septimus E, Kleinman K, Moody J, Hickok J, Avery TR, Lankiewicz J, Gombosev A, Terpstra L, Hartford F, Hayden MK, Jernigan JA, Weinstein RA, Fraser VJ, Haffenreffer K, Cui E, Kaganov RE, Lolans K, Perlin JB, Platt R. 2013. Targeted versus universal decolonization to prevent ICU infection.NEngl J Med 368:2255-2265. http://dx .doi.org/10.1056/NEJMoa1207290.
39. McDanel JS, Murphy CR, Diekema DJ, Quan V, Kim DS, Peterson EM, Evans KD, Tan GL, Hayden MK, Huang SS. 2013. Chlorhexidine and mupirocin susceptibilities of methicillin-resistant Staphylococcus aureus from colonized nursing home residents. Antimicrob Agents Chemother 57:552-558. http://dx.doi.org/10.1128/AAC.01623-12.
40. Abbasi-Montazeri E, Khosravi AD, Feizabadi MM, Goodarzi H, Khoramrooz SS, Mirzaii M, Kalantar E, Darban-Sarokhalil D. 2013. The prevalence of methicillin resistant Staphylococcus aureus (MRSA) isolates with high-level mupirocin resistance from patients and personnel in a burn center. Burns 39:650-654. http://dx.doi.org/10.1016/j.burns.2013 .02.005.
41. Jones JC, Rogers TJ, Brookmeyer P, Dunne WM, Jr, Storch GA, Coopersmith CM, Fraser VJ, Warren DK. 2007. Mupirocin resistance in patients colonized with methicillin-resistant Staphylococcus aureus in a surgical intensive care unit. Clin Infect Dis 45:541-547. http://dx.doi.org /10.1086/520663.
42. st Intersci Conf Antimicrob Agents Chemother, Chicago, IL.
43. Fridkin SK, Hageman JC, Morrison M, Sanza LT, Como-Sabetti K, Jernigan JA, Harriman K, Harrison LH, Lynfield R, Farley MM. 2005. Methicillin-resistant Staphylococcus aureus disease in three communities. NEngl J Med 352:1436-1444. http://dx.doi.org/10.1056/NEJMoa043252.
44. Klein E, Smith DL, Laxminarayan R. 2007. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 13:1840-1846. http://dx.doi.org/10.3201 /eid1312.070629.
45. Huang SS, Platt R. 2003. Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization. Clin Infect Dis 36:281-285. http://dx.doi.org/10.1086/345955.
46. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. 2005. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 26:166-174. http://dx.doi.org/10.1086 /502522.
47. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. 2003. Comparison of mortality associated with methi-cillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 36:53-59. http://dx.doi.org/10 .1086/345476.